Pharma's Almanac: Nice Insight's Content Community

Orphan Drug Designation

Orphan Drug Designation

PR-M12-19-NI-018

FDA Grants Orphan Drug Designation to Epidermolysis Bullosa Treatment

APR Applied Pharma Research s.a.

Orphan Drug Designation

Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'

Dynacure

Orphan Drug Development

An Expanding Orphan Drug Market

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

Orphan Drug Development

Navigating the Road to Successful Orphan Drug Commercialization and Launch

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

Orphan Drug

Cholangiocarcinoma Drug Receives Orphan Drug Designation from FDA

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Multiple Myeloma

Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Sutro Biopharma, Inc.

Orphan Drug Designation

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

OBI Pharma

FDA Approval

Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma

Sirnaomics, Inc.

Drug Designation

Martin Pharmaceuticals’ LIVANTRA™ Receives FDA Orphan Drug Designation in Second Indication

Martin Pharmaceuticals

Drug Designation

Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia

Alector

FDA Approval

Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer

Alteogen

PR-M12-19-NI-018

FDA Grants Orphan Drug Designation to Epidermolysis Bullosa Treatment

APR Applied Pharma Research s.a.

Orphan Drug Designation

Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'

Dynacure

Orphan Drug Development

An Expanding Orphan Drug Market

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

Orphan Drug Development

Navigating the Road to Successful Orphan Drug Commercialization and Launch

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

Orphan Drug

Cholangiocarcinoma Drug Receives Orphan Drug Designation from FDA

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Multiple Myeloma

Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Sutro Biopharma, Inc.

Orphan Drug Designation

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

OBI Pharma

FDA Approval

Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma

Sirnaomics, Inc.

Drug Designation

Martin Pharmaceuticals’ LIVANTRA™ Receives FDA Orphan Drug Designation in Second Indication

Martin Pharmaceuticals

Drug Designation

Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia

Alector

FDA Approval

Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer

Alteogen